Celldex Therapeutics Inc., of Needham, said its Phase 2b study of the experimental treatment CDX-011 — for patients with a certain type of advanced breast cancer — showed an overall survival benefit. Brean Capital called the results impressive, telling clients the drug “targets a clear and large unmet need.” Celldex’s chief medical officer said the company will have talks with the FDA this month on “a pivotal study” designed to pave the way for marketing approval.
Celldex drug trial heartens investors
December 11, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢